511 related articles for article (PubMed ID: 11724308)
1. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
2. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
Masuda H; Tanaka T; Matsuda H; Kusaba I
Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
[TBL] [Abstract][Full Text] [Related]
3. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line.
Esaki T; Nakano S; Tatsumoto T; Kuroki-Migita M; Mitsugi K; Nakamura M; Niho Y
Cancer Res; 1992 Dec; 52(23):6501-6. PubMed ID: 1423296
[TBL] [Abstract][Full Text] [Related]
4. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
5. Increased glutathione level is not involved in enhanced bleomycin sensitivity in cisplatin-resistant 2780CP cells.
Tanaka T; Kurokawa H; Matsuno K; Matsumoto S; Hayashida Y
Anticancer Res; 2008; 28(5A):2663-8. PubMed ID: 19035292
[TBL] [Abstract][Full Text] [Related]
6. Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP.
Zhan M; Liu X
Chin Med J (Engl); 1999 Apr; 112(4):336-9. PubMed ID: 11593534
[TBL] [Abstract][Full Text] [Related]
7. Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line.
Fujishima H; Nakano S; Masumoto N; Esaki T; Tatsumoto T; Kondo T; Niho Y
Oncol Res; 1997; 9(4):167-72. PubMed ID: 9268987
[TBL] [Abstract][Full Text] [Related]
8. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
Kim R; Tanabe K; Inoue H; Toge T
Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
[TBL] [Abstract][Full Text] [Related]
9. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
10. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
11. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
Shellard SA; Hosking LK; Hill BT
Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
[TBL] [Abstract][Full Text] [Related]
12. Iododeoxyuridine chemosensitization of cis-diamminedichloroplatinum(II) in human bladder cancer cells.
Chi KH; Kunugi KA; Kinsella TJ
Cancer Res; 1994 May; 54(10):2701-6. PubMed ID: 8168100
[TBL] [Abstract][Full Text] [Related]
13. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
14. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
[TBL] [Abstract][Full Text] [Related]
15. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
Yang LY; Li L; Keating MJ; Plunkett W
Mol Pharmacol; 1995 May; 47(5):1072-9. PubMed ID: 7746274
[TBL] [Abstract][Full Text] [Related]
16. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
[TBL] [Abstract][Full Text] [Related]
17. Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA.
Chu E; Lai GM; Zinn S; Allegra CJ
Mol Pharmacol; 1990 Sep; 38(3):410-7. PubMed ID: 2402230
[TBL] [Abstract][Full Text] [Related]
18. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.
Hill BT; Shellard SA; Hosking LK; Dempke WC; Fichtinger-Schepman AM; Tone T; Scanlon KJ; Whelan RD
Cancer Res; 1992 Jun; 52(11):3110-8. PubMed ID: 1591724
[TBL] [Abstract][Full Text] [Related]
20. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
